Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6

Solid Biosciences Inc.

NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.
6MWT mean increase 15.3 meters vs expected 63.5-meter decline; difference +78.8 meters.
Percent predicted FVC improved 4.1% vs expected 7.5% decline; difference +11.6%.
PODCI global, sports, transfer, upper-body scales showed sustained improvements at 1.5 years.
No new drug-related safety findings in patients with post-dosing periods up to 3.5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.